Ignite Creation Date:
2025-12-24 @ 5:12 PM
Ignite Modification Date:
2025-12-26 @ 3:15 PM
Study NCT ID:
NCT06208150
Status:
RECRUITING
Last Update Posted:
2025-12-19
First Post:
2024-01-05
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
Sponsor:
Janssen Research & Development, LLC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-01-22
Start Date Type:
ACTUAL
Primary Completion Date:
2026-04-23
Primary Completion Date Type:
ESTIMATED
Completion Date:
2028-03-31
Completion Date Type:
ESTIMATED
First Submit Date:
2024-01-05
First Submit QC Date:
None
Study First Post Date:
2024-01-17
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-12-18
Last Update Post Date:
2025-12-19
Last Update Post Date Type:
ESTIMATED